Advocate

Country: European Union

Language: Norwegian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

imidacloprid, moxidectin

Available from:

Bayer Animal Health GmbH

ATC code:

QP54AB52

INN (International Name):

imidacloprid, moxidectin

Therapeutic group:

Dogs; Cats; Ferrets

Therapeutic area:

Antiparasittiske produkter, insektmidler og repellenter

Therapeutic indications:

DogsFor hunder som lider av, eller står i fare fra, blandet parasittiske infeksjoner:behandling og forebygging av flea infestation (Ctenocephalides felis),behandling av biting lus (Trichodectes canis),behandling av øre midd infestation (Otodectes cynotis), sarcoptic skabb (forårsaket av Sarcoptes scabiei var. canis), demodicosis (forårsaket av Demodexkvalster canis),forebygging av hjerteorm sykdom (L3 og L4 larver av Dirofilaria immitis),behandling av sirkulerende microfilariae (Dirofilaria immitis),behandling av kutan dirofilariosis (voksne stadier av Dirofilaria repens)forebygging av kutan dirofilariosis (L3 larver av Dirofilaria repens),reduksjon av sirkulerende microfilariae (Dirofilaria repens),forebygging av angiostrongylosis (L4 larver og umodne voksne i Angiostrongylus vasorum),behandling av Angiostrongylus vasorum og Crenosoma vulpis,forebygging av spirocercosis (Spirocerca lupi),behandling av Eucoleus (syn. Capillaria) boehmi (voksne),behandling av øyet ormen Thelazia callipaeda (voksne),behandling av infeksjoner med gastrointestinale nematoder (L4 larver, umodne voksne og voksne i Toxocara canis, Ancylostoma caninum og Uncinaria stenocephala, voksne av Toxascaris leonina og Trichuris vulpis). Produktet kan brukes som en del av en behandlingsstrategi for loppe allergi dermatitt (FAD). CatsFor katter som lider av, eller står i fare fra, blandet parasittiske infeksjoner:behandling og forebygging av flea infestation (Ctenocephalides felis),behandling av øre midd infestation (Otodectes cynotis),behandling av notoedric skabb (Notoedres cati),behandling av lungworm Eucoleus aerophilus (syn. Capillaria aerophila) (voksne),forebygging av lungworm sykdom (L3/L4 larver av Aelurostrongylus abstrusus),behandling av lungworm Aelurostrongylus abstrusus (voksne),behandling av øyet ormen Thelazia callipaeda (voksne),forebygging av hjerteorm sykdom (L3 og L4 larver av Dirofilaria immitis),behandling av infeksjoner med gastrointestinale nematoder (L4 larver, umodne voksne og voksne i Toxocara cati og Ancylostoma tubaeforme). Produktet kan brukes som en del av en behandlingsstrategi for loppe allergi dermatitt (FAD). FerretsFor ildere som lider av, eller står i fare fra, blandet parasittiske infeksjoner:behandling og forebygging av flea infestation (Ctenocephalides felis),forebygging av hjerteorm sykdom (L3 og L4 larver av Dirofilaria immitis).

Product summary:

Revision: 23

Authorization status:

autorisert

Authorization date:

2003-04-02

Patient Information leaflet

                                OFFICIAL ADDRESS
Domenico Scarlattilaan 6
●
1083 HS Amsterdam
●
The Netherlands
An agency of the European Union
ADDRESS FOR VISITS AND DELIVERIES
Refer to www.ema.europa.eu/how-to-find-us
SEND US A QUESTION
Go to
www.ema.europa.eu/contact
TELEPHONE
+31 (0)88 781
6000
© European Medicines Agency,
2023. Reproduction is authorised provided the source is acknowledged.
Oppdaterte opplysninger om dette legemidlet til dyr er tilgjengelige
på informasjonsnettstedet for
legemidler til dyr.
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                OFFICIAL ADDRESS
Domenico Scarlattilaan 6
●
1083 HS Amsterdam
●
The Netherlands
An agency of the European Union
ADDRESS FOR VISITS AND DELIVERIES
Refer to www.ema.europa.eu/how-to-find-us
SEND US A QUESTION
Go to
www.ema.europa.eu/contact
TELEPHONE
+31 (0)88 781
6000
© European Medicines Agency,
2023. Reproduction is authorised provided the source is acknowledged.
Oppdaterte opplysninger om dette legemidlet til dyr er tilgjengelige
på informasjonsnettstedet for
legemidler til dyr.
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 31-01-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 31-01-2024
Public Assessment Report Public Assessment Report Bulgarian 29-01-2024
Patient Information leaflet Patient Information leaflet Spanish 31-01-2024
Public Assessment Report Public Assessment Report Spanish 29-01-2024
Patient Information leaflet Patient Information leaflet Czech 31-01-2024
Public Assessment Report Public Assessment Report Czech 29-01-2024
Patient Information leaflet Patient Information leaflet Danish 31-01-2024
Public Assessment Report Public Assessment Report Danish 29-01-2024
Patient Information leaflet Patient Information leaflet German 31-01-2024
Public Assessment Report Public Assessment Report German 29-01-2024
Patient Information leaflet Patient Information leaflet Estonian 31-01-2024
Public Assessment Report Public Assessment Report Estonian 29-01-2024
Patient Information leaflet Patient Information leaflet Greek 31-01-2024
Public Assessment Report Public Assessment Report Greek 29-01-2024
Patient Information leaflet Patient Information leaflet English 31-01-2024
Public Assessment Report Public Assessment Report English 29-01-2024
Patient Information leaflet Patient Information leaflet French 31-01-2024
Public Assessment Report Public Assessment Report French 29-01-2024
Patient Information leaflet Patient Information leaflet Italian 31-01-2024
Public Assessment Report Public Assessment Report Italian 29-01-2024
Patient Information leaflet Patient Information leaflet Latvian 31-01-2024
Public Assessment Report Public Assessment Report Latvian 29-01-2024
Patient Information leaflet Patient Information leaflet Lithuanian 31-01-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 31-01-2024
Public Assessment Report Public Assessment Report Lithuanian 29-01-2024
Patient Information leaflet Patient Information leaflet Hungarian 31-01-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 31-01-2024
Public Assessment Report Public Assessment Report Hungarian 29-01-2024
Patient Information leaflet Patient Information leaflet Maltese 31-01-2024
Public Assessment Report Public Assessment Report Maltese 29-01-2024
Patient Information leaflet Patient Information leaflet Dutch 31-01-2024
Public Assessment Report Public Assessment Report Dutch 29-01-2024
Patient Information leaflet Patient Information leaflet Polish 31-01-2024
Public Assessment Report Public Assessment Report Polish 29-01-2024
Patient Information leaflet Patient Information leaflet Portuguese 31-01-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 31-01-2024
Public Assessment Report Public Assessment Report Portuguese 29-01-2024
Patient Information leaflet Patient Information leaflet Romanian 31-01-2024
Public Assessment Report Public Assessment Report Romanian 29-01-2024
Patient Information leaflet Patient Information leaflet Slovak 31-01-2024
Public Assessment Report Public Assessment Report Slovak 29-01-2024
Patient Information leaflet Patient Information leaflet Slovenian 31-01-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 31-01-2024
Public Assessment Report Public Assessment Report Slovenian 29-01-2024
Patient Information leaflet Patient Information leaflet Finnish 31-01-2024
Public Assessment Report Public Assessment Report Finnish 29-01-2024
Patient Information leaflet Patient Information leaflet Swedish 31-01-2024
Public Assessment Report Public Assessment Report Swedish 29-01-2024
Patient Information leaflet Patient Information leaflet Icelandic 31-01-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 31-01-2024
Public Assessment Report Public Assessment Report Icelandic 29-01-2024
Patient Information leaflet Patient Information leaflet Croatian 31-01-2024
Public Assessment Report Public Assessment Report Croatian 29-01-2024

Search alerts related to this product

View documents history